Lupus Erythematosus Clinical Trials

60 clinical trials for Lupus Erythematosus across international registries, including 14 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Trial of Belimumab in Early Lupus — RECRUITING · PHASE4
• Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases — RECRUITING
• Cutaneous Lupus Registry — RECRUITING
• The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology. — RECRUITING · NA
• Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells — RECRUITING · PHASE2
• A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFICACY OF IMVT-1402 IN PARTICIPANTS WITH ACTIVE SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) AND/OR CHRONIC CUTANEOUS LUPUS ERYTHEMATOSUS (CCLE) WITH OR WITHOUT SYSTEMIC MANIFESTATIONS — RECRUITING · PHASE2
• A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS — RECRUITING · PHASE2
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANIFROLUMAB IN ADULTS WITH CHRONIC AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS WHO ARE REFRACTORY AND/OR INTOLERANT TO ANTIMALARIAL THERAPY — RECRUITING · PHASE3
• Methyl-donor Nutrient Supplementation and Methylation Profile in Lupus Patients With Obesity — RECRUITING · NA
• A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE 3, LONG-TERM EXTENSION STUDY TO EVALUATE CONTINUOUS SAFETY AND EFFICACY OF BIIB059 (LITIFILIMAB) IN ADULT PARTICIPANTS WITH ACTIVE SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS AND/OR CHRONIC CUTANEOUS LUPUS ERYT — RECRUITING · PHASE3
• A PHASE 3 PROGRAM TO EVALUATE THE SAFETY AND EFFICACY OF UPADACITINIB IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE SLE — RECRUITING · PHASE3
• A MULTICENTER, RANDOMIZED, DOSE-BLIND, PHASE 3 LONG-TERM EXTENSION STUDY TO EVALUATEB CONTINUOUS SAFETY AND EFFICACY OF BIIB059 IN ADULT PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS — RECRUITING · PHASE3
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIIB059 IN ADULT PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS RECEIVING BACKGROUND NONBIOLOGIC LUPUS STANDARD OF CARE — RECRUITING · PHASE3
• A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BMS-931699 VS. PLACEBO ON A BACKGROUND OF LIMITED STANDARD OF CARE IN THE TREATMENT OF SUBJECTS WIHT ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS — RECRUITING · PHASE2
• Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis — COMPLETED · PHASE1
• Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress — NOT_YET_RECRUITING · NA
• Dietary Phytoestrogens as Risk Factors for Systemic Lupus Erythematosus — COMPLETED · NA
• Identification of Modifiable Sleep-related Factors in Patients With Systemic Lupus Erythematosus. — NOT_YET_RECRUITING
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ENPATORAN IN PARTICIPANTS WITH ACTIVE CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS WITH OR WITHOUT SYSTEMIC DISEASE RECEIVING STANDARD OF CARE — NOT_YET_RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ENPATORAN IN PARTICIPANTS WITH ACTIVE CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS WITH OR WITHOUT SYSTEMIC DISEASE RECEIVING STANDARD OF CARE — NOT_YET_RECRUITING · PHASE3
• Longitudinal Study of Quality of Life and Activity in Systemic Lupus Erythematosus — COMPLETED · NA
• Transition to Adulthood Through Coaching and Empowerment in Rheumatology — COMPLETED · NA
• Description of Compliance With Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus — COMPLETED
• Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) — ACTIVE_NOT_RECRUITING · PHASE1
• CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) — WITHDRAWN · PHASE1
• Psycho-social Consequences of Systemic Lupus Erythematosus — COMPLETED
• A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease — SUSPENDED
• How much information and participation is just right? An exploratory study of the need for autonomy in outpatient care of patients with inflammatory rheumatic diseases — OTHER
• A Pilot Study to Explore the Role of Gut Flora in Lupus — WITHDRAWN
• A PHASE-1, FIRST-IN-HUMAN, RANDOMIZED, DOUBLE-BLIND, PLACEBO­-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, FOOD EFFECT, AND DRUG-DRUG INTERACTION OF ORALLY ADMINISTERED VENT-03 IN HEALTHY VOLUNTEERS — OTHER · PHASE1
• OPEN-LABEL, PHASE 1 STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AZD5492 FOLLLOWING SINGLE-ASCENDING DOSE AND STEP-UP DOSE ADMINISTRATION TO ADULT PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATUS OR IDIOPATIC INFLAMMATORY MYOPATIES — NOT_YET_RECRUITING · PHASE1
• A Study of Imvotamab in Severe Systemic Lupus Erythematosus — TERMINATED · PHASE1
• The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic — COMPLETED
• A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AUTOLOGOUS CD-19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELLS (CABA-201) IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS — NOT_YET_RECRUITING · PHASE1
• Long-term Immunogenicity of a Live Herpes Zoster Vaccine in Systemic Lupus Erythematosus (SLE) Patients — COMPLETED
• PatientSpot Formerly Known as ArthritisPower — OTHER
• Exploring Accessible Beauty for Individuals With Upper Extremity Deficits — COMPLETED
• Analysis of B Cells From Autoimmune Individuals — COMPLETED
• The Living With a Long-Term Condition Study — OTHER
• The Effects of Mesenchymal Stem Cell Secretome in Lupus Patients — COMPLETED · PHASE1
• A RANDOMIZED, BLINDED, PLACEBO-CONTROLLED, PHASE 2A, PROOF-OF-CONCEPT STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF GS 5718 IN PARTICIPANTS WITH CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) — COMPLETED · PHASE2
• A TWO-COHORT, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY TO EVALUATE EFFICACY, SAFETY AND TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS, OF EMAPALUMAB IN CHILDREN AND ADULTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) IN STILL¿S DISEASE (INCLUDING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS AND ADULT ONSET STILL¿S DISEASE) OR WITH MAS IN SYSTEMIC LUPUS ERYTHEMATOUS — COMPLETED
• Photoprovocation Testing in Subjects With Cutaneous Lupus — COMPLETED · NA
• Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord — OTHER · PHASE1
• Comparison of Complement Factors and Genetic Polymorphisms of AMD Between Patients With Systemic Lupus Erythematosus (SLE) With and Without Retinal "Pseudo-drusen-like" Deposits: Case-control Study (PL-AMD) — COMPLETED
• Not-interventional health care project “RA-Express” to implement an efficient screening system for early arthritis — OTHER
• Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic — OTHER
• A PHASE 2, LONG-TERM EXTENSION (LTE) STUDY WITH ELSUBRUTINIB AND UPADACITINIB GIVEN ALONE OR IN COMBINATION (ABBV-599) IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS WHO HAVE COMPLETED THE M19-130 PHASE 2 RANDOMIZED CONTROLLED TRIAL (RCT) — NOT_YET_RECRUITING · PHASE2
• Nurses' Health Study and Health Professionals Follow-Up Study (Dermatological Component) — COMPLETED
• A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE — COMPLETED · PHASE4

Refine this search